S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Sick of seeing others get rich in the stock market? Let Stock Advisor help (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
The 3-Stock Retirement Blueprint (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
The 3-Stock Retirement Blueprint (Ad)
NASDAQ:QTRX

Quanterix - QTRX Stock Forecast, Price & News

$8.56
+1.10 (+14.75%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.55
$8.86
50-Day Range
$7.46
$19.51
52-Week Range
$6.31
$60.92
Volume
4.67 million shs
Average Volume
445,179 shs
Market Capitalization
$315.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.20

Quanterix MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
241.1% Upside
$29.20 Price Target
Short Interest
Healthy
2.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.31mentions of Quanterix in the last 14 days
Based on 23 Articles This Week
Insider Trading
Acquiring Shares
$1.29 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($2.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

303rd out of 1,108 stocks

Analytical Instruments Industry

10th out of 31 stocks

QTRX stock logo

About Quanterix (NASDAQ:QTRX) Stock

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cowen lowered Quanterix from an "outperform" rating to a "market perform" rating in a research note on Tuesday. The Goldman Sachs Group lowered their price objective on Quanterix from $30.00 to $25.00 and set a "neutral" rating for the company in a research note on Thursday, July 14th. SVB Leerink lowered Quanterix from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $35.00 to $15.00 in a research note on Tuesday. Finally, Cowen lowered Quanterix from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $38.00 to $18.00 in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $31.20.

Quanterix Stock Performance

Shares of NASDAQ:QTRX opened at $7.46 on Wednesday. The business's 50 day moving average price is $17.03 and its 200-day moving average price is $23.03. Quanterix has a fifty-two week low of $6.31 and a fifty-two week high of $60.92. The company has a market cap of $275.35 million, a price-to-earnings ratio of -4.14 and a beta of 1.46.

Quanterix (NASDAQ:QTRX - Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.18. Quanterix had a negative return on equity of 14.70% and a negative net margin of 58.23%. The firm had revenue of $29.55 million for the quarter, compared to the consensus estimate of $28.62 million. Sell-side analysts predict that Quanterix will post -2.49 earnings per share for the current year.

Receive QTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter.

QTRX Stock News Headlines

Quanterix (NASDAQ:QTRX) Lowered to Market Perform at Cowen
Why Quanterix Shares Plunged by Nearly 55% Today
Quanterix (QTRX) Scheduled to Post Quarterly Earnings on Monday
See More Headlines
Receive QTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter.

QTRX Company Calendar

Last Earnings
11/04/2021
Today
8/10/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QTRX
Fax
N/A
Employees
460
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.20
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+393.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
5 Analysts

Profitability

Net Income
$-57,690,000.00
Pretax Margin
-58.40%

Debt

Sales & Book Value

Annual Sales
$110.56 million
Book Value
$12.03 per share

Miscellaneous

Free Float
33,883,000
Market Cap
$315.95 million
Optionable
Not Optionable
Beta
1.46

Key Executives














QTRX Stock - Frequently Asked Questions

Should I buy or sell Quanterix stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QTRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTRX, but not buy additional shares or sell existing shares.
View QTRX analyst ratings
or view top-rated stocks.

What is Quanterix's stock price forecast for 2022?

5 Wall Street analysts have issued 12-month price targets for Quanterix's shares. Their QTRX share price forecasts range from $15.00 to $60.00. On average, they predict the company's stock price to reach $29.20 in the next twelve months. This suggests a possible upside of 241.1% from the stock's current price.
View analysts price targets for QTRX
or view top-rated stocks among Wall Street analysts.

How have QTRX shares performed in 2022?

Quanterix's stock was trading at $42.40 at the beginning of 2022. Since then, QTRX stock has decreased by 79.8% and is now trading at $8.56.
View the best growth stocks for 2022 here
.

When is Quanterix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our QTRX earnings forecast
.

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.13. The firm had revenue of $26.68 million for the quarter, compared to analysts' expectations of $23.84 million. Quanterix had a negative trailing twelve-month return on equity of 14.70% and a negative net margin of 58.23%. During the same quarter last year, the firm posted $0.07 EPS.

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.

What other stocks do shareholders of Quanterix own?

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (1.90%), Baillie Gifford & Co. (1.71%), Royce & Associates LP (0.68%), CWM LLC (0.56%), Assenagon Asset Management S.A. (0.44%) and Candriam S.C.A. (0.24%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Martin D Madaus, Masoud Toloue and Michael A Doyle.
View institutional ownership trends
.

How do I buy shares of Quanterix?

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $8.56.

How much money does Quanterix make?

Quanterix (NASDAQ:QTRX) has a market capitalization of $315.95 million and generates $110.56 million in revenue each year. The company earns $-57,690,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Quanterix have?

The company employs 460 workers across the globe.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The official website for the company is www.quanterix.com. The company can be reached via phone at (617) 301-9400 or via email at ir@quanterix.com.

This page (NASDAQ:QTRX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.